Investors

Press Releases

Press Releases

Apr 10, 2021

Kymera Therapeutics Presents Late-Breaking Preclinical Data Highlighting Superiority of Dual-Targeting Activity of IRAKIMiD Degrader KT-413 at AACR Annual Meeting 2021

Apr 09, 2021

Kymera Therapeutics to Present New Results from Non-Interventional Study in Patients with Hidradenitis Suppurativa at the Society for Investigative Dermatology (SID) 2021 Annual Meeting

Mar 16, 2021

Kymera Therapeutics Appoints Elena Ridloff, CFA, to Board of Directors

Mar 11, 2021

Kymera Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides a Business Update

Mar 02, 2021

Kymera Therapeutics Announces First-in-Human Dose in Phase 1 Trial of KT-474, a First-in-Class IRAK4 Protein Degrader to Treat Immune-Inflammatory Diseases

Feb 25, 2021

Kymera Therapeutics to Present at Upcoming March Investor Conferences

Feb 04, 2021

Kymera Therapeutics to Present at Upcoming February Investor Conferences

Feb 03, 2021

Kymera Therapeutics Strengthens Leadership with Key Appointments and Promotions

Jan 12, 2021

Kymera Therapeutics Announces Key 2021 Goals and Milestones to Support its Evolution into a Fully Integrated Degrader Medicines Company

Jan 05, 2021

Kymera Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021

Investor Contact

Paul Cox
VP, Investor Relations and Communications
pcox@kymeratx.com

Christopher F. Brinzey
Westwicke, an ICR Company for Kymera Therapeutics
chris.brinzey@westwicke.com
+ 1 339.970.2843

Media Contact

media@kymeratx.com

Lissette L. Steele
Verge Scientific Communications for Kymera Therapeutics
lsteele@vergescientific.com
+1 202.930.4762

Sign Up for Email Alerts